Sino Biopharmaceutical (Sino Biopharmaceutical) Additional Paid-In Capital : $1,734 Mil(As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Additional Paid-In Capital?

Sino Biopharmaceutical's quarterly additional paid-in capital increased from Jun. 2022 ($0 Mil) to Dec. 2022 ($1,787 Mil) but then stayed the same from Dec. 2022 ($1,787 Mil) to Jun. 2023 ($1,734 Mil).

Sino Biopharmaceutical's annual additional paid-in capital increased from Dec. 2020 ($0 Mil) to Dec. 2021 ($1,971 Mil) but then declined from Dec. 2021 ($1,971 Mil) to Dec. 2022 ($1,787 Mil).

Sino Biopharmaceutical Additional Paid-In Capital Historical Data

The historical data trend for Sino Biopharmaceutical's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Additional Paid-In Capital Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,971.28

1,787.43

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															1,971.28	-	1,787.43	1,734.34	-

Sino Biopharmaceutical Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Sino Biopharmaceutical Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SBHMY:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.